Drug Channel Updates
Timely updates on drug shortages, launches, recalls, and more.
Top shortages
Acetamin/Cod 300-30mg 100’s Manufacturer backing this product. Quota delays causing this issue.
Albut/Iprat 3-0.5mg/3ml 12x5UD Product being allocated. Increased demand causing this issue.
Amoxicillin 400mg/5ml 75ml Manufacture on back order. Increased demand causing this issue.
Cefdinir 250mg/5ml 60ml Product being allocated. Increased demand causing this issue.
Diclofenac Sod 1% Top 100gm Product being allocated. Cipla is the only manufacturer with RX-quality products. All others have gone OTC.
Diltiazem 240mg Er 30’s Manufacture on back order. Awaiting vendor update.
Farxiga Tab 10mg 30’s No information available.
Gentamicin 0.3% 5ml Item being allocated due to manufacturer exiting the marketplace.
Lantus Solostar Pen 3ml 5’s No release date available.
Levlbutrl Tart HFA 45mcg 15gm Product being allocated. Manufacture delays causing this issue.
Mounjaro 2.5mg/0.5ml LX No release date available.
Mounjaro 7.5mg/0.5ml LX Next release date is late March. Full recovery TBD.
Mounjaro 10mg/0.5ml LX No release date available.
Mounjaro 12.5mg/0.5ml LX Next release date is mid-April. Full recovery TBD.
Mounjaro 15mg/0.5ml LX Some short date products available.
Naltrexone HCL 50mg 30’s API delays and one vendor exiting the marketplace.
Nyamyc 100mu/gm Top 60gm Product being allocated. Delays in manufacturing plus increased demand causing this issue.
Omega-3 Acid Ethyl Est 1gm 120’s Apotex is discontinuing this item sometime in April which will put pressure on others. Item expected to be allocated.
Progesterone 100mg 100’s Product being allocated. Long-term issue. Aurobindo hopes to increase capacity sometime this summer.
Trulicity 1/5mg/0.5ml LX 4’s Next release date early April. Full recover TBD.
Trulicity SDV 4.5mg/5ml Next release date not available.
Wegovy 0.25mg Pens 4’s Product on allocation, next release date late March. Short-dated product being shipped.
Drug Launches
The latest insights on the drug market.
Recent Launches
No new launches at this time.
Upcoming Launches
Rayos (prednisone) is a $120 million market and is expected to launch in early April, but it may be delayed again.
Isentress (raltegrivir potassium) is a $281 million market. Due to litigation, this launch will be delayed for some time.
Myrbetriq (mirabegron) is a $2.4 billion market and is scheduled to launch early May. However, a new patent has been presented, which may delay this launch.
Oxtellar XR (oxcarbazepine) is a $210 million market and is scheduled to launch sometime in early September. No source vendor has been selected.
Sandostatin LAR (octretide acetate) is a $1.5 billion market and is scheduled to launch early June. No source vendor has been selected.
Sprycel (dasatinib) is a $2.3 billion market. It’s scheduled to launch sometime in mid-September. No source vendor has been selected.
Victoza (liraglutide recombinant) is a $3.7 billion market and is expected to launch sometime in late June. No source vendor has been selected.
Day 181
Alphagan P 0.1% (brimonidine tartrate) is a $243 million market. Additional vendors expected quarter 1.
Ongluza (saxagliptin hydrochloride) is a $133 million market. Mylan is our source provider. It will be available sometime in April.
Onexton (clindamycin phos/benzoyl perox gel w/pump) is a $117 million market and will be available in April. Taro is the source vendor.
Pradaxa (dabigatrain etexilate mesylate) is a $112 million market and will be available to others in May. Apotex will be the source vendor.
Condylox (podofilox gel) is an $11 million market. It will be available to others in June.
Prolensa (bromfenac sodium) is a $186 million market. Will be available to others in July. Lupin will be the source vendor.
Indocin (indomethacin oral susp) is a $5 million market and will be available in July. ANI will be the source vendor.
BromSite (bromfenac sodium drops) is a $30 million market and will be available in August. Lupin will be our source vendor.
Rectiv (nitroglycerin oint) is a $23 million market and will be available in August. Cosette will be our source vendor.
Recalls
The most recent recall information with return forms.
Par Pharmaceutical
Treprostinil 20mg/20ml injection
Reason for recall: Potential presence of silicone particulate matter
Company Name: Endo International, Par Pharmaceutical
Various
Dietary supplements for sexual enhancement
Reason for recall: Undeclared Sildenafil and/or Tadalafil
Company name: Pyramid Wholesale